Active	Status	Sponsor type	Region	Phase	Filter
4 Active 4 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hofman, Paul Pr
OraGrowtH210, NCT04614337 / 2020-000874-92: Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency ( Trial)	Completed	2	82	Europe, US, RoW	LUM-201, rhGH Norditropin® pen (34 µg/kg)	Lumos Pharma, Lumos Pharma	Growth Hormone Deficiency	09/24	09/24
MelBase, NCT02828202: Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary	Recruiting	N/A	6000	Europe	Biological, Tissular, Quality of life	Assistance Publique - Hôpitaux de Paris, National Cancer Institute (NCI)	Malignant Melanoma	03/26	03/26
CIRCULAR, NCT04912687: Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients	Recruiting	N/A	580	Europe	EGFR gene mutation analysis on liquid biopsy	Institut Bergonié, AstraZeneca	Non Small Cell Lung Cancer, Advanced Solid Tumor	01/25	01/26
MRD LUNG, NCT06111807: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC	Recruiting	N/A	248	Europe	ctDNA	University Medical Center Groningen, LungenClinic Grosshansdorf, Centre Hospitalier Universitaire de Nice	Lung Cancer Stage III	12/25	07/30
Biggs, Diane
No trials found